Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eisai CoESALF 74 EV-to-EBITDA is 12.06 as of Jul. 24, 2026, which is 89% above its 10-year median of 6.39. GuruFocus rates ESALF with a GF Score™ of 74/100 and a GF Value™ of $35.00 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 742 Drug Manufacturers companies, Eisai Co ranks worse than 50.81% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eisai Co's enterprise value is $7,720 Mil.
Eisai Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $640 Mil. Therefore, Eisai Co's EV-to-EBITDA for today is 12.06.
The historical rank and industry rank for Eisai Co's EV-to-EBITDA or its related term are showing as below:
ESALF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.27 Med: 6.39 Max: 61.28
Current: 12.74
During the past 13 years, the highest EV-to-EBITDA of Eisai Co was 61.28. The lowest was 2.27. And the median was 6.39.
ESALF's EV-to-EBITDA is ranked worse than 50.81% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.96
vs ESALF: 12.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Eisai Co (OTCPK:ESALF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eisai Co's share price for today is $26.175.
Eisai Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.917.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Eisai Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eisai Co's EV-to-EBITDA falls into.
Eisai Co's current Enterprise Value is $7,720 Mil.
Eisai Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $640 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (ESALF) has a EV-to-EBITDA of 12.06 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eisai Co. This is 89% above median its historical median of 6.39. Over the past decade, Eisai Co's EV-to-EBITDA has ranged from 2.27 to 61.28. According to the industry distribution chart, Eisai Co ranks #377 out of 742 companies in the Drug Manufacturers industry, placing it in the top 50.8%.
Is Eisai Co's EV-to-EBITDA too high?
Eisai Co's current EV-to-EBITDA of 12.06 is 89% above median its 10-year median of 6.39. Over the past 10 years, this metric has ranged from a low of 2.27 to a high of 61.28. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Eisai Co's value of 12.06 is 6.9% below this industry median. Based on the distribution chart, Eisai Co ranks #377 out of 742 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #377 out of 742 companies for EV-to-EBITDA. This places Eisai Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. Eisai Co's value of 12.06 is 6.9% below this benchmark. Historically, Eisai Co's own EV-to-EBITDA has ranged from 2.27 to 61.28 over the past decade. While the company's 10-year median is 6.39 vs. the industry median of 12.96, Eisai Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eisai Co's current EV-to-EBITDA of 12.06 is 6.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eisai Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current EV-to-EBITDA is 12.06, which is 89% above median its own 10-year median of 6.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Modestly Undervalued. The stock's GF Value™ is $35.00, compared to a current price of $26.18 — trading 25.2% below its estimated fair value. The current EV-to-EBITDA is 12.06, which is 89% above median its 10-year median of 6.39 and 6.9% below the Drug Manufacturers industry median of 12.96. Eisai Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Eisai Co (ESALF), the current EV-to-EBITDA is 12.06 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $26.18 is trading 25.2% below its estimated GF Value™ of $35.00.
GuruFocus considers Eisai Co to be Modestly Undervalued.
Key valuation signals for ESALF:
EV-to-EBITDA: 12.06 (89% above median its 10-year median of 6.39)
GF Value™: $35.00 vs. price of $26.18 (25.2% below fair value)
Industry Position: 6.9% below the Drug Manufacturers median (#377 of 742)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score
Get the complete analysis for ESALF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
